Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Rhabdomyosarcoma × Radiotherapy × Clear all

Phase

Phase 3 9 Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 26 Carcinoma, Non-Small-Cell Lung 26 Lung Neoplasms 21 Head and Neck Neoplasms 17 Lymphoma 15 Gliosarcoma 14 Squamous Cell Carcinoma of Head and Neck 13 Central Nervous System Neoplasms 13 Sarcoma 12 Esophageal Neoplasms 11 Glioma 10 Leukemia 9 Breast Neoplasms 9 Rectal Neoplasms 8 Prostatic Neoplasms 8 Brain Neoplasms 8 Pancreatic Neoplasms 7 Lymphoma, Follicular 6 Esophageal Squamous Cell Carcinoma 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Neoplasms 5 Neoplasm Metastasis 5 Melanoma 5 Lymphoma, Large B-Cell, Diffuse 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Carcinoma, Renal Cell 5 Astrocytoma 5 Adenocarcinoma of Lung 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4

Interventions

Temozolomide 8 Irinotecan 7 Vincristine 6 Nivolumab 2 temsirolimus 1 talazoparib 1 surufatinib 1 silmitasertib 1 regorafenib 1 prexasertib 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 liposomal doxorubicin 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 irinotecan sucrosofate 1 ganitumab 1 eribulin 1 efineptakin alfa 1 dostarlimab 1 dinutuximab 1 copanlisib 1 bempegaldesleukin 1 atezolizumab 1 adavosertib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Thrombopoietin 1 Receptor Protein-Tyrosine Kinases 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡